ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0963

Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRDs)

Gordon Lam1, Andrew Laster2, Sarah McCarter2, Heather Gladue3, Ahmad Kashif2, Erin Siceloff2, Victoria Lackey3, Cheryl Robertson3, Ashley Toci2 and Leonard Calabrese4, 1Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, 2Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, 3Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, 4Cleveland Clinic, Cleveland, OH

Meeting: ACR Convergence 2021

Keywords: Biologicals, Clinical practice guidelines, COVID-19, Disease-Modifying Antirheumatic Drugs (Dmards), Infection

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Abstracts: Infection-related Rheumatic Disease (0962–0965)

Session Type: Abstract Session

Session Time: 10:45AM-11:00AM

Background/Purpose: AIIRD patients may have a blunted immune response to the COVID-19 vaccines, but this is largely uncharacterized as these individuals were not included in clinical trials. Vaccine response may be affected by patients’ underlying disease processes and the systemic immunomodulatory therapies used to treat them, although the evidence for this is uncertain. To better understand the immunogenicity of the COVID-19 vaccines in this patient population and their treatment regimens, we quantified humoral responses to the SARS-CoV-2 spike protein in AIIRD patients.

Methods: This exploratory, descriptive, prospective cohort study enrolled patients from a single-specialty practice in Charlotte, NC who received the BNT162b2 (Pfizer), mRNA-1273 (Moderna) or Ad26COV2.S (Johnson & Johnson) vaccine from 3/17/21-5/14/21. Those with prior COVID-19 by self-report were excluded. We collected demographics, AIIRD diagnoses and immunomodulatory regimens of these patients. Antibody (Ab) testing was performed at least 14 days after completion of their vaccine series. SARS-CoV-2 IgG Ab levels to the S1 spike antigen RBD were measured using a semi-quantitative assay (Siemens Atellica; Quest). Associations between clinical characteristics and Ab responses were evaluated.

Results: Characteristics of 291 AIIRD patients studied are listed in Table 1. Overall, 71% developed an Ab response with a mean Ab titer of 12.72 (< 1 index). There was no difference based on gender. The likelihood of an absent Ab response increased with age, and there was a decline in mean levels with aging in Ab+ patients.

Treatment associations are listed in Table 2. Patients receiving rituximab were less likely to develop an Ab response (13%) and had a lower mean Ab titer (7.55) compared to the overall cohort. Dosing appeared to affect response rates with a single dose (1000 mg) Ab+ rate of 38% compared to a paired dose (1000 mg x2) rate of 7% (Table 3). Patients receiving abatacept IV were also less likely to develop an Ab response (45%). Detectable antibodies were seen in nearly all patients on JAKi (91%), belimumab (86%), TNFi (82%), IL-17i (80%), IL-6i (78%), IL-23i (100%) and IL-12/23i (100%).

Without concomitant targeted therapy, Ab+ rates with mycophenolate (75%) and MTX (80%) were decreased compared to sulfasalazine (100%), leflunomide (100%) and azathioprine (89%). 82% of patients receiving prednisone without biologics were Ab+ (average daily dose <10 mg). Overall dose effect is shown in Table 3.

Conclusion: A majority (71%) of AIIRD patients developed detectable anti-SARS-CoV-2 RBD Abs. Ab response rates and titers were age dependent. Patients receiving rituximab and abatacept IV were less likely to develop an Ab response with the former having a dose effect. Among csDMARDs, response rates were decreased in patients receiving MTX and mycophenolate. Low dose prednisone without biologics did not appear to influence Ab+ rates. Limitations of this study include its single center, non-randomized design and lack of residual confounder measures. Additional measures of humoral immune response and T cell function are also needed. However, this real-world study may provide further guidance for COVID-19 vaccination in patients with AIIRDs on immunomodulatory drugs.

Table 1. Demographics and Clinical Characteristics of Patients with Autoimmune and Inflammatory Rheumatic Disease patients

Table 2. Patient immunomodulatory therapies and vaccine responses. IgG antibodies to SARS CoV_2 S1 RBD antigen were measured using a semi-quantitative chemiluminescent immunoassay (Siemens Atelllica IM/Siemens Atellica IM Analyzer; QUEST ) in which negative/nonreactive was <1.0, and positive/reactive was reported from 1.00 to 20.00 or > 20.00 . https://www.siemens-healthineers.com/en-us/laboratory-diagnostics/assays-by-diseases-conditions/infectious-disease-assays/sars-cov_2-igg-assay

Table 3. Dose effects of rituximab and prednisone on vaccine responses in AIIRD patients


Disclosures: G. Lam, Abbvie, 2, 6, Aurinia, 6, AstraZeneca, 6, Bristol Myers Squibb, 2, 6, Horizon, 6, Janssen, 1, 6, Sanofi, 2, 6, Pfizer, 1, 6, UCB, 2, 6, GlaxoSmithKline, 6; A. Laster, Pfizer, 6, Genentech, 6, Eli Lilly, 2, 6, Amgen, 1, 2, 6, Crescendo, 1, 6, Exagen, 6, Novartis, 1, 6; S. McCarter, None; H. Gladue, GSK, 6, Horizon pharmaceuticals, 6; A. Kashif, None; E. Siceloff, Abbvie, 1, 6, Pfeizer, 1, Novartis, 1, 6; V. Lackey, None; C. Robertson, None; A. Toci, None; L. Calabrese, Lilly, 2, BMS, 2, Genentech, 2.

To cite this abstract in AMA style:

Lam G, Laster A, McCarter S, Gladue H, Kashif A, Siceloff E, Lackey V, Robertson C, Toci A, Calabrese L. Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRDs) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/immunogenicity-of-covid-19-vaccines-in-patients-with-autoimmune-and-inflammatory-rheumatic-diseases-aiirds/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunogenicity-of-covid-19-vaccines-in-patients-with-autoimmune-and-inflammatory-rheumatic-diseases-aiirds/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology